128 related articles for article (PubMed ID: 33558989)
1. Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy.
Pasqualetti F; Gonnelli A; Orlandi P; Palladino E; Giannini N; Gadducci G; Mattioni R; Montrone S; Calistri E; Mazzanti CM; Franceschi S; Ortenzi V; Scatena C; Zavaglia K; Fanelli GN; Morganti R; Santonocito O; Bocci G; Naccarato GA; Paiar F
Invest New Drugs; 2021 Aug; 39(4):1159-1165. PubMed ID: 33558989
[TBL] [Abstract][Full Text] [Related]
2. Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy.
Pasqualetti F; Gonnelli A; Cantarella M; Delishaj D; Molinari A; Ortenzi V; Carbone F; Montrone S; Ursino S; Franceschi S; Morganti R; Orlandi P; Di Desidero T; Mazzanti CM; Zavaglia K; Naccarato AG; Bocci G; Paiar F
Invest New Drugs; 2018 Apr; 36(2):340-345. PubMed ID: 28965273
[TBL] [Abstract][Full Text] [Related]
3. Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy.
Pasqualetti F; Orlandi P; Simeon V; Cantarella M; Giuliani D; Di Desidero T; Gonnelli A; Delishaj D; Lombardi G; Sechi A; Sanson M; Zagonel V; Paiar F; Danesi R; Guarini S; Bocci G
Mol Neurobiol; 2018 Feb; 55(2):1396-1404. PubMed ID: 28150230
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
5. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
6. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
8. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
9. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.
Seidlitz A; Siepmann T; Löck S; Juratli T; Baumann M; Krause M
Radiat Oncol; 2015 Aug; 10():172. PubMed ID: 26276734
[TBL] [Abstract][Full Text] [Related]
10. Association between RAD 51 rs1801320 and susceptibility to glioblastoma.
Franceschi S; Tomei S; Mazzanti CM; Lessi F; Aretini P; La Ferla M; De Gregorio V; Pasqualetti F; Zavaglia K; Bevilacqua G; Naccarato AG
J Neurooncol; 2016 Jan; 126(2):265-70. PubMed ID: 26511493
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
Kong XT; Nguyen NT; Choi YJ; Zhang G; Nguyen HN; Filka E; Green S; Yong WH; Liau LM; Green RM; Kaprealian T; Pope WB; Nghiemphu PL; Cloughesy T; Lassman A; Lai A
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1195-1203. PubMed ID: 29722661
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
14. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
16. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Butowski N; Chang SM; Lamborn KR; Polley MY; Pieper R; Costello JF; Vandenberg S; Parvataneni R; Nicole A; Sneed PK; Clarke J; Hsieh E; Costa BM; Reis RM; Hristova-Kazmierski M; Nicol SJ; Thornton DE; Prados MD
Neuro Oncol; 2011 Dec; 13(12):1331-8. PubMed ID: 21896554
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide.
Malmström A; Łysiak M; Åkesson L; Jakobsen I; Mudaisi M; Milos P; Hallbeck M; Fomichov V; Broholm H; Grunnet K; Poulsen HS; Bratthäll C; Strandeus M; Papagiannopoulou A; Stenmark-Askmalm M; Green H; Söderkvist P
Pharmacogenomics J; 2020 Apr; 20(2):213-219. PubMed ID: 31624332
[TBL] [Abstract][Full Text] [Related]
20. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
